Search clinical trials for: Placebo Aliskiren

Total 53533 results

Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
Novartis Pharmaceuticals

Terminated

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) (ALTITUDE)

Cardiovascular Disease | Type 2 Diabetes Mellitus

Spain, China, United States, Belgium, Colombia, South Africa, Italy, United Kingdom, Germany, Hungary, Japan, Taiwan, Turkey, Netherlands, Greece, Switzerland, Austria, France, Thailand, Argentina, Canada, Singapore, Lithuania, Sweden, ... and more
Christiana Care Health Services

Completed

The Effect of Renin Inhibition on Nerve Function in Diabetes

Diabetes

United States
Novartis Pharmaceuticals
The Cleveland Clinic

Completed

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients (AQUARIUS)

Coronary Artery Disease (CAD) | Coronary Atherosclerosis

Italy, Spain, Hungary, Australia, United States, Belgium, Canada, Germany, France, Argentina, Poland
Wake Forest University Health Sciences
Novartis Pharmaceuticals

Completed

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction (Aliskiren)

Heart Failure

United States
Novartis Pharmaceuticals

Terminated

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Diabetic Macular Edema

Denmark, United States
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Novartis Pharmaceuticals

Completed

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT)

Acute Decompensated Heart Failure | Congestive Heart Failure

Colombia, Czech Republic, India, Italy, Belgium, Turkey, Argentina, France, Germany, Israel, Spain, Canada, Taiwan, United States, Singapore, Russian Federation, Philippines, Slovakia, Sweden, Hungary, Finland, Poland, Romania, Brazil
Brigham and Women's Hospital
Novartis

Terminated

Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients

Kidney Failure, Chronic | Kidney Disease

United States
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); Novartis; National Institute...

Terminated

The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

Endothelial Dysfunction

United States
Novartis

Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Hypertension

United States
University Medical Center Groningen

Terminated

Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment (ARIANA-CHF-RD)

Heart Failure | Kidney Failure

Netherlands
Novartis

Completed

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Myocardial Infarction

United States, Argentina, Belgium, Canada, Colombia, Czech Republic, Denmark, Germany, Hungary, India, Israel, Italy, Korea, Republic of, Netherlands, Norway, Poland, Russian Federation, Slovakia, Spain, Sweden, Turkey, United Kingdom and more
Ohio State University
Novartis

Terminated

Aliskiren Effect on Aortic Plaque Progression (ALPINE)

Atherosclerosis

United States
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Completed

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

Diabetes Type 2

United States
Vitae Pharmaceuticals, Inc.
Brigham and Women's Hospital

Completed

Direct Renin Inhibition and the Kidney

Renal Function

United States
Chinese University of Hong Kong

Completed

Aliskiren for Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

Hong Kong
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan

Unknown

Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure

Congestive Heart Failure

Taiwan
Wayne State University
Novartis

Unknown

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)

Hypertension

United States
Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
Novartis Pharmaceuticals

Completed

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

Hypertension

India
Novartis

Completed

SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Hypertension

Japan
University of Campania "Luigi Vanvitelli"
IRCCS San Raffaele

Unknown

RAAS Inhibitor Drugs in Dialysis Patients

Hypertension | End Stage Renal Disease
Novartis

Completed

Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren

Hypertension

United States
University of Alabama at Birmingham
Novartis

Terminated

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Hypertension | Diabetes | Pre-hypertension

United States
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Hypertension

Estonia, France, Iceland, India, Italy, Korea, Republic of, Lithuania, Spain, Venezuela
Novartis

Completed

SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension

Hypertension

Japan
Novartis

Completed

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Hypertension

United States, Germany
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital

Unknown

Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure

Heart Failure

Taiwan
Taipei Veterans General Hospital, Taiwan
National Science Council, Taiwan

Unknown

Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure (VACHF)

Heart Failure

Taiwan
University of Erlangen-Nürnberg Medical School

Completed

Aliskiren on Retinal Vasculature Treatment Study (ARTS)

Arterial Hypertension

Germany
Novartis

Completed

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Heart Failure

Germany, United States
Novartis

Completed

Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Diabetes Type 2

Denmark
Novartis

Completed

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

Hypertension

United States
Novartis

Completed

SPP100 Dose Finding Study in Japan

Hypertension

Japan
Novartis

Completed

Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension

Hypertension

Japan
Mika Lehto

Unknown

Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. (RALF)

Atrial Fibrillation

Finland
Novartis

Completed

Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

Diabetes Mellitus, Type 2

Denmark
Novartis

Completed

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

End Stage Renal Disease

Germany
Mayo Clinic

Withdrawn

Aliskiren in Patients With Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy

United States
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

Heart Failure

Germany, Lithuania
Novartis

Completed

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Hypertension

United States, Argentina, Colombia, France, Germany, India, Spain
Novartis

Completed

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Hypertension

Singapore, Hungary, Czech Republic, United Kingdom
Novartis Pharmaceuticals

Completed

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Hypertension

United States, Taiwan, Italy, Slovakia, Canada, Spain, Puerto Rico
Novartis

Completed

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus (ViVID)

Hypertension

United States
Novartis

Completed

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal (ASSERTIVE)

Hypertension

Brazil, Canada, Ecuador, Germany, Hungary, Korea, Republic of, Malaysia, Mexico, Panama, Philippines, Singapore, Slovakia, Spain, Turkey, United Kingdom, Venezuela
Novartis

Completed

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients (ALIAS)

Essential Hypertension

France
Novartis

Completed

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Hypertension

Hungary, Poland, United States, Belgium, Brazil

3

Subscribe